Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03589118
Other study ID # P160946J
Secondary ID 2017-A02986-47
Status Recruiting
Phase N/A
First received
Last updated
Start date October 4, 2018
Est. completion date December 2020

Study information

Verified date July 2019
Source Assistance Publique - Hôpitaux de Paris
Contact Alain BAUMELOU, MD, Ph.D
Phone 01 42 16 05 75
Email alain.baumelou@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Craving arises in response to an affective tone that is associated with perceptual representations of a sensory object, rather than directly in response to the object.

The investigators presume that qi gong functions to decouple pleasant and unpleasant experience from habitual reactions by removing the affective bias that fuels such emotional reactivity. Qi gong training may specifically target the associated learning process with an emphasis on the critical link between affect and craving in an addictive loop.


Description:

The treatment of severe addiction to alcohol and one other or more psychoactive substances sometimes requires hospitalization for complex withdrawal. The medical term " sevrage complexe " is used in this file for hospitalization of patients with multiple addictions or with multiple comorbidities. In the french regulation the duration of hospitalization for " sevrage complexe " is at least 13 days.

The acute period of the first week is sufficient for physical weaning. A period relay for maintaining abstinence beyond the acute phase is a difficult stage. During this period the psychological craving related to the absence of the product causes dysphoria, stress, emotivity and increased difficulty in managing psychological aggression. The risk of relapse is then maximal and favored by many insults of everyday life.

Qi gong is classified by US National Library of Medicine as a mind-body therapy (MBT). It's an ancient traditional Chinese health practice believed to have special healing and recovery power. Today millions of people practice qi gong in China and around the world to treat various diseases. Qi gong is an ecole of breath, relaxation, guided imagery and inward attention. Practice of qi gong is believed to help cleanse the body of toxins, restore energy balance, reduce stress and anxiety. The Baduanjin qigong is one of the most common form of Chinese qi gong.

When going through withdrawal, craving is a psychological urge to administer a discontinued medication or recreational drug. Craving episodes may be triggered by seeing objects or experiencing moments that are associated with the drug or usage of it, and this phenomenon is termed post-acute withdrawal syndrome.

The main goal of our study is to demonstrate a reduction of craving during alcohol and coaddictions withdrawal. This demonstration is of first importance: first for the well-being of the patient during the first weeks after withdrawal, second for drug savings, and third abstinence rate because many authors consider that craving intensity is correlated with relapses risk.

The mind-body techniques of traditional Chinese medicine, as Qigong, are inscribed the number of current approaches in residential treatment. Their transmission would be an additional contribution to the stabilization via active management and motivated patient himself on his health.

The compulsion associated with addictive behavior can be defined as a pathological change in brain plasticity. The pathological learning process induced by the repeated use of the substance is causing behavioral control loss in the vulnerable individual.

Considering the impulsive nature of craving, this study will investigate the driving dynamics of impulses: Trieb "push". Return to the perception supported by the development of attention gestures leaning on the breath, puts us ahead of the motor action and is potentially a mean of influencing compulsive process.


Recruitment information / eligibility

Status Recruiting
Enrollment 186
Est. completion date December 2020
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria

- Meets DSM 5 criteria for alcohol use disorder and other substance use disorders

- Alcohol is one of the major abused substances if using multiple substances

- Severity of the disorder defines by the necessity of a complex withdrawal hospitalization.

- Used alcohol in the 3 weeks before hospitalization

- Seeks addiction treatment

- Patient willing to adhere to the study protocol (e.g. attend all visits and follow-ups in the next 3 months).

- Age = 18

- Negative pregnancy test (ßHCG) for women of child bearing potential

- Signed informed consent

- Affiliation to the French health insurance (recipient or assign)

- Oral and written comprehension of the french langage

Non-inclusion criteria

- Pose a current suicidal risk including active suicidal ideation and suicide attempt in the past 30 days

- Non stabilized severe psychiatric comorbidities such as bipolar disorder, schizophrenia, … (at the investigator's discretion)

- Pregnant or breastfeeding women

- Decompensated cirrhosis, liver encephalopathy, neurological complications, severe cognitive impairment and any other severe somatic comorbidity (at the investigator's discretion)

- Currently participated in other interventional clinical study

- Individuals placed under guardianship

- Patient deprived of freedom

Study Design


Intervention

Other:
Qi Gong sessions
13 sessions of Qi Gong in a 9 weeks period

Locations

Country Name City State
France Hôpital Saint ELOI Montpellier
France Hôpital L'ARCHET Nice
France Groupe Hospitalier Pitié Salpêtrière Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Variation of craving intensity Variation of craving intensity on a Vvisual aAnalogic sScale (VAS) between baseline and the end of the treatment. The intensity is measured by "not at all" (score of 0) and "craving as bad as it could be" or "the most I've ever felt " (maximum score of 10), self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents his craving intensity.
The score is determined by measuring the distance on the 10-cm line between the "no craving" anchor and the patient's mark.
Change in VAS from baseline to 9 weeks treatment
Secondary Evolution over time of craving intensity Craving intensity measured with 14-items Obsessive Compulsive Drinking Scale (OCDS).
OCDS score is the sum of two subscales scores. Obsessive Subscale is calculated from items 1 to 6, maximal subscore is 20 (worse outcome).
Compulsive subscale is calculated from items 7 to 14.
0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline
Secondary Difference in treatment retention Difference in treatment retention (permanence rate) 3 weeks and 9 weeks post-baseline
Secondary Evolution over time of total alcohol consumption Alcohol consumption assessed with Time Line Follow Back (TLFB) 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline
Secondary Evoluation over time of anxiety Anxiety questions sum score of Hospital Anxiety and Depression scale (HAD scale). Seven questions are related to anxiety (total A). Anxiety is measured by the sum score questions 1 , 4, 6 , 8, 10 , 12, 14. . Non : Total A = 1,3,5,7,9,11,13
The maximum score being equal to 21 :
0-7: normal; 8-10 bordeline abnormal (borderline case); 11-21 : abnormal (case)
0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline
Secondary Evolution over time of depression Depression questions sum score of Hospital Anxiety and Depression scale (HAD scale).
Seven questions are related to the depressive dimension (total D). Depression is measured by the sum score questions 2, 3, 5 , 7, 9 , 11, 13 Non: Total D : 2,4,6,8,10,12,14.
The maximum score being equal to 21 :
0-7: normal; 8-10: bordeline abnormal (borderline case); 11-21: abnormal (case)
0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline
Secondary Psycological qualitative evaluation Qualitative evaluation assessed with clinical notes 1 day, 2 days, 3 days, 4 days, 5 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks and 9 weeks post-baseline
Secondary Evolution over time of total alcohol consumption measured by GGT biomarker GGT Gamma glutamyl transpeptidase levels in UI/I at 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline
Secondary Evolution over time of total alcohol consumption measured by Carbohydrate-Deficient Transferrin (CDT) marker CDT levels in % at 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline
Secondary Evolution over time of total alcohol consumption measured by Mean Globular Volume (MGV) marker MGV levels in fL at 0 day, 3 days, 5 days, 3 weeks and 9 weeks post-baseline
See also
  Status Clinical Trial Phase
Completed NCT02901041 - Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism Phase 3
Completed NCT03340051 - Remote Alcohol Monitoring and Episodic Thinking N/A
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Completed NCT02705898 - Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women N/A
Completed NCT02486900 - Neurofeedback & Alcohol Dependence N/A
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Completed NCT02197598 - Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use Phase 4
Recruiting NCT02385643 - The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients N/A
Completed NCT01828866 - Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT01342549 - Treatment Strategy for Alcohol Use Disorders in Veterans With TBI Phase 3
Completed NCT02193204 - Chronic Alcohol, Stress Inflammatory Response and Relapse Risk N/A
Completed NCT01176591 - HBPL Study of the Impact of the NK1 Antagonist Aprepitant Phase 2
Completed NCT01165541 - A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency Phase 2
Completed NCT01056484 - Mindfulness Meditation for Health Phase 2
Completed NCT00585780 - Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse Phase 1/Phase 2
Completed NCT00607620 - Disseminating Organizational SBI Services at Trauma Centers N/A
Completed NCT00884884 - Aripiprazole and Topiramate on Free-Choice Alcohol Use Phase 2/Phase 3
Completed NCT00463346 - Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism Phase 3